

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Mukherjee et al.

Application No. 10/019,833

Filed: October 18, 2001

For: UTEROGLOBIN IN THE TREATMENT OF IGA
MEDIATED AUTOIMMUNE DISORDERS

Examiner: Not yet assigned

Date: January 29, 2002



Art Unit: Not yet assigned

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on January 29, 2002 as First Class Mail in an envelope addressed to: BOX PCT, COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

William D. Noonan

William D. Noonan, M.D.
Attorney for Applicant

BOX PCT
COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination of the above-referenced application, please amend the application as follows:

In the specification:

On page 1, line 4, please insert the following paragraph:

--PRIORITY CLAIM

This is a § 371 U.S. national stage of PCT/US00/09979, filed April 13, 2000, which was published in English under PCT Article 21(2), and claims the benefit of U.S. Application No. 60/130,434, filed April 21, 1999.--

The following abstract (which is also submitted on a separate page) should be inserted as page 54 of the specification:

-- Abstract

**UTEROGLOBIN IN THE TREATMENT OF
IgA MEDIATED AUTOIMMUNE DISORDERS**

Uteroglobin has been discovered to prevent IgA mediated diseases, such as IgA nephropathy, by preventing the deposition of IgA-Fibronectin immunocomplexes in tissues